Spine-Tech (SPYN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Spine-Tech (SPYN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Royalcoachman who wrote (213)	12/7/1997 12:34:00 AM
From: ForYourEyesOnly	of 242

Thank you for your response. We are both busy, so I will keep my response simple. 1. What is the reason that the SPYN product is only to be used in 1/4 of the total number of procedures? 2. Suppose that SYPN gets the 100,000 operations per year, and makes $300M per year in revenue. If they have 15% profits on this, then they will make $45M/year in profits, or about $4.5 per share. At $33/ a share, is this really overvalued? 3. As another poster has kindly pointed out, Q to Q sequential revenue increases of 12% is excellent, and if sustainable would turn into excellent Y to Y revenue increases. Good luck.... THC

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next